We introduce ourselves
Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Alnylam was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development. We are committed to serve European patients. As part of our transition from a research to a commercial organization, Alnylam is heavily investing in setting up a logistical infrastructure able to serve patients in Europe. We are creating highly-skilled jobs, while building a diverse and inclusive workforce. Over the past year, Alnylam has established International Operations in The Netherlands and Switzerland, opened new offices in France, Germany, Italy, Spain, Sweden and the UK, and set up supply chain activities in Germany, Ireland and The Netherlands.
